X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Elder Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs ELDER PHARMA - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD ELDER PHARMA LUPIN LTD/
ELDER PHARMA
 
P/E (TTM) x 19.9 -0.2 - View Chart
P/BV x 2.7 0.1 2,673.0% View Chart
Dividend Yield % 0.9 0.0 -  

Financials

 LUPIN LTD   ELDER PHARMA
EQUITY SHARE DATA
    LUPIN LTD
Mar-17
ELDER PHARMA
Jun-14
LUPIN LTD/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs1,750380 460.5%   
Low Rs1,384188 735.9%   
Sales per share (Unadj.) Rs387.4491.2 78.9%  
Earnings per share (Unadj.) Rs56.6-3.2 -1,780.0%  
Cash flow per share (Unadj.) Rs76.814.4 533.3%  
Dividends per share (Unadj.) Rs7.500-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs298.9376.5 79.4%  
Shares outstanding (eoy) m451.5820.54 2,198.5%   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x4.00.6 699.5%   
Avg P/E ratio x27.7-89.3 -31.0%  
P/CF ratio (eoy) x20.419.7 103.5%  
Price / Book Value ratio x5.20.8 694.9%  
Dividend payout %13.20-   
Avg Mkt Cap Rs m707,5135,833 12,128.7%   
No. of employees `00016.8NA-   
Total wages/salary Rs m28,4952,179 1,307.7%   
Avg. sales/employee Rs Th10,418.3NM-  
Avg. wages/employee Rs Th1,697.0NM-  
Avg. net profit/employee Rs Th1,523.0NM-  
INCOME DATA
Net Sales Rs m174,94310,089 1,734.0%  
Other income Rs m1,065257 415.1%   
Total revenues Rs m176,00810,346 1,701.3%   
Gross profit Rs m44,931-792 -5,673.9%  
Depreciation Rs m9,122361 2,524.9%   
Interest Rs m1,5252,756 55.3%   
Profit before tax Rs m35,349-3,653 -967.7%   
Minority Interest Rs m-720-   
Prior Period Items Rs m830-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m9,785125 7,818.7%   
Profit after tax Rs m25,575-65 -39,134.8%  
Gross profit margin %25.7-7.8 -327.2%  
Effective tax rate %27.7-3.4 -808.0%   
Net profit margin %14.6-0.6 -2,256.9%  
BALANCE SHEET DATA
Current assets Rs m119,5429,240 1,293.7%   
Current liabilities Rs m61,2069,998 612.2%   
Net working cap to sales %33.3-7.5 -444.0%  
Current ratio x2.00.9 211.3%  
Inventory Days Days7646 164.1%  
Debtors Days Days9060 149.9%  
Net fixed assets Rs m131,66010,124 1,300.5%   
Share capital Rs m903206 439.1%   
"Free" reserves Rs m134,0735,582 2,401.7%   
Net worth Rs m134,9767,734 1,745.3%   
Long term debt Rs m56,4784,889 1,155.2%   
Total assets Rs m266,07322,882 1,162.8%  
Interest coverage x24.2-0.3 -7,431.8%   
Debt to equity ratio x0.40.6 66.2%  
Sales to assets ratio x0.70.4 149.1%   
Return on assets %10.211.8 86.6%  
Return on equity %18.9-0.8 -2,242.2%  
Return on capital %19.322.3 86.4%  
Exports to sales %03.0 0.0%   
Imports to sales %00.4 0.0%   
Exports (fob) Rs mNA307 0.0%   
Imports (cif) Rs mNA43 0.0%   
Fx inflow Rs m81,885307 26,707.3%   
Fx outflow Rs m21,506125 17,163.8%   
Net fx Rs m60,378181 33,303.0%   
CASH FLOW
From Operations Rs m41,14811,754 350.1%  
From Investments Rs m-25,287-561 4,511.5%  
From Financial Activity Rs m4,332-6,762 -64.1%  
Net Cashflow Rs m20,1934,432 455.6%  

Share Holding

Indian Promoters % 46.6 39.6 117.7%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 7.5 150.7%  
FIIs % 31.9 16.8 189.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 36.1 28.0%  
Shareholders   98,259 16,479 596.3%  
Pledged promoter(s) holding % 0.0 77.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  DIVIS LABORATORIES  ALEMBIC LTD  

Compare LUPIN LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Feb 23, 2018 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE LUPIN LTD WITH

MARKET STATS